Stock Market Reviews

CTSO (Cytosorbents Corporation) News

Get the latest news, insights, and market updates on CTSO (Cytosorbents Corporation). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• CTSO: CytoSorbents High Margin Revenue Growth Supports Price Target of $4.00
  By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT 3rd Quarter 2025 Financial & Operating Results CytoSorbents (NASDAQ:CTSO) reported 3rd quarter 2025 financial and operating results which exceeded our expectations. The company generated revenues of $9.5 million, an increase of 10.1%, or 4.0% on a constant currency basis, compared to $8.6 million in the prior year
  Nov 17, 2025 - $CTSO
• Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London
  CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in one-on-one meetings with investors at the Jefferies Global Healthcare Conference, being held on November 17-20, 2025 in London, United Kingdom.
  Nov 17, 2025 - $CTSO
• CytoSorbents Corp (CTSO) Q3 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...
  CytoSorbents Corp (CTSO) reports a 10% revenue increase and outlines plans for achieving cash flow breakeven by Q1 2026 amid regulatory and market challenges.
  Nov 14, 2025 - $CTSO
• CytoSorbents: Q3 Earnings Snapshot
  PRINCETON, N.J. (AP) — CytoSorbents Corp. CTSO) on Thursday reported a loss of $3.2 million in its third quarter. On a per-share basis, the Princeton, New Jersey-based company said it had a loss of 5 cents.
  Nov 13, 2025 - $CTSO
• CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update
  CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the third quarter ended September 30, 2025, and recent business highlights.
  Nov 13, 2025 - $CTSO
• Cytosorbents (CTSO) Q3 2025 Earnings Transcript
  Need a quote from a Motley Fool analyst? Phillip Chan: Thank you very much, Adanna, and good afternoon, everyone. Cytosorbents Corporation continues to make solid progress as we execute on our long-term growth strategy.
  Nov 13, 2025 - $CTSO
• CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London
  CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that its Chief Executive Officer, Dr. Phillip Chan, and Chief Financial Officer, Mr. Peter Mariani, will attend and participate in one-on-one meetings with investors at the Jefferies Global Healthcare Conference in London on November 18-19, 2025.
  Nov 11, 2025 - $CTSO
• CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights
  CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2025 financial results and recent business highlights after the market close on Thursday, November 13, 2025.
  Oct 30, 2025 - $CTSO
• In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer
  CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, honors the life and legacy of Dr. Robert Hawes Bartlett, MD (1939-2025), the company's former Chief Medical Officer from 2008-2017, who passed away last week at age 86.
  Oct 28, 2025 - $CTSO
• CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen
  CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today its strong scientific presence at the upcoming European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting, the world's largest gathering for the global cardiothoracic community, taking place October 8–11, 2025 in Copenhagen, Denmark. The meeting is expected to attract more than 5,000 attendees from
  Sep 29, 2025 - $CTSO